Depression is the third leading cause of disability in the world. Depressive symptoms may
be reduced within several weeks after the start of conventional antidepressants, but …

Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that
purpose, has garnered marked interest over the past two decades as an emerging treatment …

Biomarkers have transformed modern medicine but remain largely elusive in psychiatry,
partly because there is a weak correspondence between diagnostic labels and their …

Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset
antidepressant properties, but little is known regarding which patients are most likely to …

Background The N-methyl-D-aspartate glutamate receptor antagonist ketamine, delivered
via an intravenous route, has shown rapid antidepressant effects in patients with treatment …

Increased rostral anterior cingulate cortex (rACC) activity has emerged as a promising
predictor of treatment response in depression, but neither the reliability of this relationship …

Neurons in the primate dorsolateral prefrontal cortex (dlPFC) generate persistent firing in the
absence of sensory stimulation, the foundation of mental representation. Persistent firing …

Cognitive abnormalities are a core feature of depression, and biases toward negatively
toned emotional information are common, but are they a cause or a consequence of …

After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent
advances in our understanding of the neurobiology of psychedelics, such as lysergic acid …

Traumatic brain injury (TBI) is a leading cause of disability. Sequelae can include functional
impairments and psychiatric syndromes such as post-traumatic stress disorder (PTSD) …